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Abstract
5′AMP-activated kinase (AMPK) constitutes a hub for cellular meta-
bolic and growth control, thus representing an ideal therapeutic
target for prostate cancers (PCas) characterized by increased lipo-
genesis and activation of mTORC1 pathway. However, whether
AMPK activation itself is sufficient to block cancer cell growth
remains to be determined. A small molecule screening was per-
formed and identified MT 63–78, a specific and potent direct AMPK
activator. Here, we show that direct activation of AMPK inhibits
PCa cell growth in androgen sensitive and castration resistant PCa
(CRPC) models, induces mitotic arrest, and apoptosis. In vivo, AMPK
activation is sufficient to reduce PCa growth, whereas the allelic
loss of its catalytic subunits fosters PCa development. Importantly,
despite mTORC1 blockade, the suppression of de novo lipogenesis
is the underpinning mechanism responsible for AMPK-mediated
PCa growth inhibition, suggesting AMPK as a therapeutic target
especially for lipogenesis-driven PCas. Finally, we demonstrate that
MT 63–78 enhances the growth inhibitory effect of AR signaling
inhibitors MDV3100 and abiraterone. This study thus provides a
rationale for their combined use in CRPC treatment.
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Introduction
Metabolism in cancer cells is reprogrammed to facilitate the incorpo-
ration of nucleotides, amino acids, and lipids into the biomass
needed to produce a new cell (Vander Heiden et al, 2009). Increased
de novo fatty acid (FA) and cholesterol synthesis is a hallmark of
prostate cancer (PCa) and correlates with tumor progression and
poorer prognosis (reviewed in Pelton et al, 2012; Zadra et al, 2013).
Increased protein synthesis due to alterations in phosphatase and
tensin homologue/phosphatidylinositol 3-kinase/Akt/mammalian
target of rapamycin (PTEN/PI3K/Akt/mTOR) pathway is also a
common feature of both primary and metastatic PCas (Majumder &
Sellers, 2005), and is associated with increased lipogenesis (Van de
Sande et al, 2002). However, despite promising preclinical results,
targeting mTOR complex 1 (mTORC1) with rapamycin and its ana-
logues failed to show clinical efficacy in PCa (Amato et al, 2008)
due to the emergence of survival feedback loops (O’Reilly et al,
2006; Carracedo et al, 2008; Rodrik-Outmezguine et al, 2011) or
concomitant development of a tumor-driven lipogenic phenotype
(Menendez & Lupu, 2007). The side effects of existing FA synthesis
inhibitors have thus far precluded their clinical use in cancer (Flavin
et al, 2011). Thus, alternative strategies to target these pathways in
PCa patients are in great need.
5′ AMP-activated kinase (AMPK) is an energy sensor serine/
threonine kinase that stands at the crossroads linking cell metabo-
lism and oncogenesis. It is a heterotrimeric complex (composed of a
catalytic a subunit and regulatory b and c subunits) that responds
to an increased AMP/ATP ratio by turning on ATP-generating path-
ways, while switching off ATP-consuming ones (Hardie & Carling,
1997). AMPK directs the switch from an anabolic to a catabolic state
both by phosphorylating key metabolic targets, and by regulating
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EMBO Molecular Medicine Vol 6 |N o4 | 2013 519their gene expression (Hardie, 2007). AMPK activation requires
phosphorylation of Thr172 within the a subunit by an upstream
Ser/Thr protein kinase, mainly the tumor suppressor liver kinase
beta 1 (LKB1) and the calcium/calmodulin-dependent protein
kinase kinase-b (CaMKKb) (Woods et al, 2003; Hawley et al, 2005).
Germline inactivating mutations of LKB1 are responsible for the
Peutz-Jeghers hereditary cancer syndrome. Somatic mutations of
LKB1 are also found in a significant fraction of non-small cell lung
carcinomas (NSCLCs) and cervical tumors, thus suggesting that
LKB1/AMPK axis may act as a tumor suppressor (Shackelford &
Shaw, 2009). When pharmacologically activated, AMPK exerts plei-
tropic effects resulting in the suppression of tumorigenesis and
tumor progression, including inhibition of mTORC1 signaling mem-
bers tuberous sclerosis complex 2 (TSC2) and Raptor, FA and cho-
lesterol biosynthesis, cell cycle progression, as well as induction of
autophagy and apoptosis (Shaw, 2009; Fogarty & Hardie, 2010). In
contrast, AMPK loss fosters tumor progression (Faubert et al, 2013).
Epidemiologic and experimental evidence using metformin and
AICAR suggest that AMPK activation is a valid anti-cancer strategy
(Xiang et al, 2004; Evans et al, 2005; Bowker et al, 2006; Zakikhani
et al, 2008). However, these activators are known to have additional
molecular targets and AMPK-independent effects, leaving unan-
swered the question of whether AMPK activation per se is necessary
and sufficient to affect tumor growth (Ben Sahra et al, 2008, 2011;
Kalender et al, 2010; Santidrian et al, 2010). Direct targeting of
AMPK with A-769662 (Abbott Laboratories) has initially shown
promising results in the treatment of metabolic disorders and cancer
(Cool et al, 2006; Huang et al, 2008). However, AMPK-independent
toxic effects and reduced efficacy in cancer cells have been recently
reported (Moreno et al, 2008; Garcia-Garcia et al, 2009). Thus,
development of novel AMPK direct activators is the focus of intense
efforts (Pang et al, 2008; Lee et al, 2011).
Androgens are the major drivers of PCa carcinogenesis/progres-
sion and androgen deprivation therapy (ADT) is an effective
first-line therapy for advanced PCa. Despite good initial responses,
most patients relapse within several years with a more aggressive
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Figure 1. The novel small molecule MT 63–78 induces a direct activation of AMPK and prevents its dephosphorylation.
A Molecular structure of MT 63–78 (MW = 326 Da).
B Dose-dependent phosphorylation of GST-ACC peptide (1–150) by human recombinant AMPK a1b1c1, after 30-min incubation with MT 63–78. AMP (25 lM) was used
as positive control.
C AMPK dephosphorylation assay, as described in Supplementary materials and methods. Recombinant AMPK a1b1c1 (100 ng) was incubated with 100 ng of
upstream kinase calcium/calmodulin-dependent protein kinase kinase-b (CaMKKb). Phosphorylation of AMPK was then detected in the presence or absence of
protein phosphatase 2C alpha (PP2Ca, 26 ng) and in the presence or absence of MT 63–78 (5 lM) using an antibody against the residue Thr172 on the a subunit.
Source data are available for this figure.
Figure 2.M T 63–78 activates AMPK in PCa cells without altering the energy levels.
A Dose-response activation of AMPK and phosphorylation of its direct targets Acetyl CoA Carboxylase (ACC) and Raptor in PCa cells.
B AMPK activity assay as described in Supplementary materials and methods. Results are expressed as normalized average  s.d. of three independent samples. One-
way ANOVA test, followed by Dunnett’s post hoc test for multiple comparisons was performed and adjusted P values were calculated (LNCaP: **P = 0.0074 MT 5 lM
versus DMSO; ***P < 0.0001 MT 25 lM versus DMSO; ***P < 0.0001 MT 50 lM versus DMSO; ***P = 0.0002 AICAR versus DMSO. PC3: ***P = 0.00022 MT 5 lM
versus DMSO; ***P < 0.0001 MT 25 lM versus DMSO; ***P < 0.0001 MT 50 lM versus DMSO; ***P < 0.0001 MT 100 lM versus DMSO; ***P = 0.000173 AICAR
versus DMSO). RLU = relative luminescence units..
C Measurment of ATP. 24-h incubation with metformin (Metf, 2.5 mM), 2-deoxyglucose (2-DG, 10 mM), and olygomycin (OM, 1 lM) was used as control. Results are
expressed as means  s.d. of three independent samples. One-way ANOVA test, followed by Dunnetts post hoc test for multiple comparisons was performed and
adjusted P values were calculated (LNCaP: **P = 0.0093 Metf versus DMSO; ***P = 0.0002 2-DG versus DMSO; ***P = 0.0002 OM versus DMSO. PC3: ***P = 0.0002
2-DG versus DMSO).
D Measurment of ADP. Twelve hour incubation 2-deoxyglucose (2-DG, 10 mM), and olygomycin (OM, 1 lM) was used as control. Results are expressed as means
 s.d. of three independent samples. One-way ANOVA test, followed by Dunnetts post hoc test for multiple comparisons was performed and adjusted P values were
calculated (LNCaP: *P = 0.0172 2-DG versus DMSO; *P = 0.0208 OM versus DMSO).
E Expression levels of phosphorylated ACC, Raptor, AMPK and their correspondent total forms in wild-type (wt) and AMPK a1
/ and a2
/ MEFs.
F AMPK activity in LNCaP and PC3 cells transfected with AMPK b1 subunit siRNA, following treatment with MT 63–78 (MT) or DMSO. Results are expressed as
normalized average  s.d. of three independent samples. One-way ANOVA test, followed by Bonferroni post hoc test for multiple comparisons was performed and
adjusted P values were calculated. (LNCaP scramble: ***P = 1.92E-13 MT versus DMSO; LNCaP b1 siRNA P = 0.1179 MT versus DMSO. PC3 scramble: ***P < 0.0001
MT versus DMSO; PC3 b1 siRNA: P = 0.2455 MT versus DMSO. n.s. = non significant. Western blot analysis shows the rate of AMPK b1 silencing.
Data information: Analyses in (A–F) were performed after 30-min incubation with MT 63–78, at indicated concentrations.
Source data are available for this figure.
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reactivation occurs through a variety of mechanisms (Yuan et al,
2013). Hence targeting the AR remains a critical component of the
current CRPC therapies, including the AR antagonist MDV3100, and
the inhibitor of androgen synthesis abiraterone (Higano & Craw-
ford, 2011). However, emergence of treatment resistance to these
new drugs represents a major limitation (Yuan et al, 2013). Previ-
ous groups have shown AR-induced de novo lipogenesis, which is
enhanced during the emergence of androgen independence to
contribute to the survival/growth of CRPC cells (Swinnen et al,
1997; Ettinger et al, 2004). Since AMPK activation negatively
regulates the expression/activity of lipogenic transcriptional factors
(SREBPs, Sterol Regulatory Element-Binding Proteins) and the
major lipogenesis and cholesterol synthesis enzymes, we reasoned
that combinatorial regimens of AMPK activators and AR pathway
inhibitors might result in a therapeutic benefit and overcome
resistance to ADT.
In this study, we use a novel small molecule AMPK activator to
investigate whether AMPK per se plays an anti-cancer role in PCa,
and whether this can be monitored in vivo by PET imaging. We
dissect the molecular underpinning mechanisms of AMPK medi-
ated-growth inhibition and we seek to determine the effect of
AMPK activation in CRPC and its combination with AR signaling
inhibitors.
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MT 63–78 selectively activates AMPK in prostate cancer cells
The small molecule MT 63–78 (now Debio 0930) was identified in a
targeted screening using purified human recombinant AMPK
a1b1c1 (Fig 1A). Oral bioavailability and pharmacokinetic charac-
terization of the compound is provided in Supplementary Fig 1A.
Using a cell-free assay, we demonstrated that MT 63–78 allosterically
activates recombinant AMPK in a dose-dependent manner (Fig 1B).
In addition, MT 63–78, like AMP, inhibits AMPK dephosphorylation
on Thr172 by protein phosphatase 2C alpha (Fig 1C). We tested
whether MT 63–78 was able to activate AMPK in PCa cells, using
androgen-dependent LNCaP (PTEN null) and androgen-independent
PC3 (PTEN and p53 null) cell lines as models. We observed a dose-
dependent phosphorylation of the two major AMPK targets Acetyl-
CoA Carboxylase (ACC) on Ser79 and of Raptor on Ser792, after
30 min of treatment. A corresponding increase in Thr172
phosphorylation on the AMPK a subunit was also observed
(Fig 2A). AMPK activity induced by MT 63–78 was significantly
increased in both cell lines in a dose-dependent manner
(EC50 = 25 lM) (Fig 2B). This increase was significantly stronger
compared to treatment with the current available AMPK activator A-
769662 (Abbott Laboratories) and AICAR (Supplementary Fig 1B).
In contrast to metformin, 2-deoxyglucose, and oligomycin, addition
of the compound did not cause any changes in intracellular ATP,
ADP levels in LNCaP and PC3 cells, demonstrating that AMPK acti-
vation by MT 63–78 is not an indirect effect of increased energy
stress (Fig 2C and D). We also confirmed these data in HepG2 cells
by measuring ATP, ADP, and AMP levels using high-performance
liquid chromatography (HPLC). Reduction in ATP levels and
increased ADP, AMP levels were only observed at 200 lM of the
compound, which is far beyond the concentrations used in this
study (Supplementary Fig 2).
To evaluate the specificity of MT 63–78, AMPK a1
/ and
a2
/ and wild-type (wt) mouse embryonic fibroblasts (MEFs)
were incubated with MT 63–78 for 30 min. In contrast to wt
MEFs, no phosphorylation of ACC and Raptor was observed in
AMPK a1
/ and a2
/ MEFs (Fig 2E). We also screened MT 63–
78 at 5 and 25 lM in cell-free assays against a panel of 93 pro-
tein kinases other than AMPK (Kinase Profiler, Millipore). Only 2
kinases (IGF-1R, Flt3) were slighltly activated at the highest con-
centration, whereas the majority of the kinases were not stimu-
lated by either of the two concentrations, including the rat
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Figure 3. LKB1 is not essential for MT 63–78-mediated activation of AMPK.
A LKB1 and CaMKKb expression in PCa cells. HeLa cells were used as negative control.
B Dose-response activation of AMPK, phosphorylation of ACC and Raptor in LKB1 null HeLa (left) and DU145 (right) cells, after 30-min incubation with MT 63–78, at
indicated concentrations.
C AMPK activity in HeLa cells treated with CaMKKb inhibitor STO-609. HeLa cells were incubated with or w/o STO-609 (10 lg/ml) for 2.5 h prior to incubation with MT
63–78 (25 lM) for 30 min. Results are expressed as normalized average  s.d. of three independent samples. One-way ANOVA test, followed by Bonferroni post hoc
test for multiple comparisons was performed and adjusted P values were calculated (HeLa: ***P < 0.0001 MT versus DMSO; HeLa + STO-609: P = 0.0605 MT versus
DMSO), n.s. = non significant. One sample for each condition was used for western blot analysis.
D AMPK activity and western blot analysis in wt and LKB1
/ MEFs treated as in C. Results are expressed as normalized average  s.d. of three independent samples.
One-way ANOVA test, followed by Bonferroni post hoc test for multiple comparisons was performed and adjusted P values were calculated (MEF LKB1wt + STO-609:
***P < 0.0001 MT versus DMSO; MEF LKB1
/ + STO-609: P > 0.09999 MT versus DMSO). n.s. = non significant.
Source data are available for this figure.
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kinase family (SIK, ARK5, MARK1). At 25 lM, six kinases were
marginally inhibited, but only in one case (MST1) the inhibition
was more than 50% (Supplementary Fig 3).
The compound exerts its effect by binding to the regulatory b
subunit. To discriminate between the b1 and b2 subunits, we tested
the in vitro activity of four different AMPK heterotrimeric complexes
(a1b1c1, a2b1c1, a1b2c1, a2b2c1), following incubation with MT
63–78, A-769662, and AMP. We observed that both MT 63–78 and
A-769662 show maximal AMPK activation in b1 subunit-containing
heterotrimers (a1b1c1, a2b1c1) and a stronger effect for A-769662.
At high doses MT 63–78 was also able to activate b2 subunit-
containing heterotrimers, whereas A-769662 showed no activation
(a1b2c1) or low activation (a2b2c1), suggesting a low-affinity bind-
ing of MT 63–78 to the b2 subunit, especially when b2 is complexed
with the a2 subunit (Supplementary Fig 4A). However, using PCa
cell models, we observed that b1 subunit knock down significantly
reduces the basal activity of AMPK (80 and 92% for LNCaP and
PC3, respectively) and totally abolishes its activation by MT 63–78
(Fig 2F). In contrast, in b2 subunit-silenced LNCaP and PC3 cells
AMPK activity and ACC phosphorylation were still increased
(although at lower extent) when cells were treated with MT 63–78
(Supplementary Fig 4B and C). This suggests that MT 63–78
activates AMPK mainly by binding the b1 subunit in a cell-
based context.
Taken together, these results show that the small molecule MT
63–78 is a specific and potent tool for studying the effect of a direct
activation of AMPK in PCa.
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Figure 4.M T 63–78 inhibits PCa cell growth and soft agar colony formation.
A Growth curves of LNCaP and PC3 cells treated with MT 63–78 and AICAR for 4 days, at indicated concentrations.
B Relative growth of CL1, 22Rv1, C4-2, C4-2B cells, following 48-h treatment with MT 63–78. Results are expressed as percentage of cells compared to control (DMSO)
 s.d. of three independent samples. For CL1 experiments, six independent samples were used. One-way ANOVA test, followed by Dunnetts post hoc test for
multiple comparisons was performed and adjusted P values were calculated (CL1: ***P = 0.00047 MT 10 lM versus DMSO; ***P < 1E-04 MT 25 lM versus DMSO;
***P < 1E-04 MT 50 lM versus DMSO. 22Rv1: *P = 0.0471 MT 10 lM versus DMSO; **P = 0.0021 MT 25 lM versus DMSO; ***P = 0.0004 MT 50 lM versus DMSO.
C4-2: **P = 0.0011 MT 10 lM versus DMSO; ***P < 0.0001 MT 25 lM versus DMSO; ***P < 0.0001 MT 50 lM versus DMSO. C4-2B: ***P < 1E-08 MT 10 lM versus
DMSO; ***P < 1E-08 MT 25 lM versus DMSO; ***P < 1E-08 MT 50 lM versus DMSO).
C Relative growth of wt and AMPK a1
/ and a2
/ MEFs, following 3-day treatment with MT 63–78 (25 lM), AICAR (1 mM), and metformin (Metf, 2.5 mM). Results
are expressed as percentage of cells compared to control (DMSO)  s.d. of three independent samples. One-way ANOVA test, followed by Tukey’s post hoc test for
multiple comparisons was performed and adjusted P values were calculated. (MEFs wt: ***P = 5.91E-07 MT versus DMSO; ***P = 3.75E-06 AICAR versus DMSO;
***P = 6.14E-06 Metf versus DMSO. AMPK a1
/ and a2
/ MEFs: P = 0.1373 MT versus DMSO non-significant (n.s.); ***P = 8.79E-09 AICAR versus DMSO;
***P = 4.27E-08 Metf versus DMSO;
###P = 1.41E-07 AICAR versus MT;
###P = 1.37E-06 Metf versus MT.
D Number of PC3 colonies in soft agar after 3-week treatment with 1 and 5 lM (positive control) MT 63–78. Results are expressed as number of colonies  s.d. of
three independent experiments. One-way ANOVA test, followed by Dunnetts post hoc test for multiple comparisons was performed and adjusted P values were
calculated (*P = 0.027 MT 1 lM versus DMSO; **P = 0.0029 MT 5 lM versus DMSO). Photographs of colonies (10 × magnification) are shown.
E Growth curve of PC3 cells treated with 1 lM MT-63–78 or vehicle for 9 days. Results are expressed as number of viable cells  s.d. of three independent samples.
Two way ANOVA test, followed by SIDAKs multiple comparison test was performed. No significant difference was observed.
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tumor suppressor LKB1
Activation of AMPK requires phosphorylation of Thr172 mainly by
LKB1 and CaMKKb (Woods et al, 2003; Hawley et al, 2005). Both
upstream kinases are expressed in normal prostate cells and in PCa
cells, except for DU145 cells, which are LKB1 null (Fig 3A). We trea-
ted DU145 and HeLa cells (the model commonly used for LKB1 defi-
ciency) with MT 63–78 and we observed a dose-dependent
activation of AMPK in both cell lines (Fig 3B). HeLa as well as wt
and LKB1
/ MEFs were then exposed to the CaMKKb inhibitor
STO-609, prior to incubation with the compound. STO-609 almost
completely abolished AMPK activation by MT 63–78 as well as the
phosphorylation of AMPK downstream targets ACC and raptor in
HeLa and LKB1
/ MEFs, whereas STO-609 did not have any signif-
icant effect on wt MEFs (Fig 3C and D).
These results suggest that activation of AMPK in response to MT
63–78 is independent of LKB1 when CaMKKb is functional, opening
new perspectives for the treatment of LKB1-null tumors.
Direct activation of AMPK inhibits androgen dependent and CRPC
cell growth
Growth of AR + and AR LNCaP and PC3 cells was analyzed over
4 days, following the addition of MT 63–78. A dose-dependent
decrease in cell number, concomitant to the activation of AMPK
signaling was observed (Fig 4A). The growth inhibitory effect of
MT 63–78 was also evaluated in several AR+ CRPC cell models
(CL1, C4-2, and 22Rv1), as well as in the C4-2B subline derived
from bone metastasis. Forty-eight hours incubation with MT 63–78
significantly reduced cell growth in all CRPC cell models (Fig 4B).
High concentrations of the compound (50 lM) exerted a more
moderate effect in immortalized non-transformed iPrEC and
RWPE-1 cells, and low concentrations (5 lM) do not affect RWPE-
1 cells, while still inhibiting PCa cell growth. These data suggest
that the compound mostly affects cancer cell growth (Supplemen-
tary Fig 5A and B). We compared the efficacy of MT 63–78 and A-
769662 in inhibiting AR sensitive and CRPC PCa cell growth and
showed that MT 63–78 has 16–40 times higher potency than A-
769662 (Supplementary Fig 5C). In addition, the growth inhibitory
effect of MT 63–78 was not limited to PCa cells, and included
LKB1-null A549 and BRAF mutated (V600E) KTC-1 cells (Supple-
mentary Fig 6).
Using AMPK a1
/ and a2
/ MEFs, we confirmed that MT 63–
78-mediated inhibition of cell growth is strictly dependent on the
functional activity of AMPK (Fig 4C) in contrast to AICAR and
metformin, as previously shown by other groups (Ben Sahra et al,
2008; Park et al, 2009; Gonzalez-Girones et al, 2013). At concentra-
tions that do not affect cell number (1 lM), MT 63–78 still inhibits
anchorage-independent growth (Fig 4D and E).
MT 63–78 induces mitotic arrest and apoptosis
Cell cycle analysis using propidium iodide (PI) showed that 24-h
treatment with MT 63–78 induces a significant enrichement in the
G2/M population in both androgen sensitive and CRPC cell mod-
els (Fig 5A). G2-M arrest was particularly dramatic in the p53
null PC3 cells, suggesting a p53-independent effect. In contrast, in
LNCaP cells, G2/M arrest was more evident after 48-h treatment
(Supplementary Fig 7A). These finding were also confirmed in
other tumor models (Supplementary Fig 7A). In depth morpholog-
ical and molecular characterization indicated that MT 63–78
induces arrest in M phase. We observed accumulation of rounded
and detached cells, and chromosome condensation in pro-meta-
phase (Fig 5B). Western blot analysis showed increased phos-
phorylation of histone H3 (marker of mitosis) in treated cells and
accumulation of the mitotic regulator cyclin B1 (Fig 5C), suggest-
ing that arrest takes place before anaphase when most of cyclin
B1 is degradated (Clute & Pines, 1999; Chang et al, 2003), most
likely during pro-metaphase. In contrast to nocodazole treatment,
no significant changes in cdc2 expression were observed (Supple-
mentary Fig 7B). Moreover, the viable cells recovered from the
conditioned media of MT 63–78 treated dishes showed high levels
of cyclin B1 and positivity for phospho-histone H3, in keeping
with the known looser attachment of cells to the substrate during
mitotic rounding (Fig 5C). Consistent with the accumulation of
cyclin B1, we observed accumulation and/or increased activation
of key mitotic kinases such as Aurora kinases A, B, and Polo-like
kinase 1 (PLK1) (Fig 5C). Evidence is now accumulating that a
fine-tuned spatial and temporal activation of AMPK at the mitotic
apparatus is required for correct spinde assembly/orientation,
chromosal segregation, and proper cell division (Lee et al, 2007;
Vazquez-Martin et al, 2009a,b; Thaiparambil et al, 2012). Thus,
our results suggest that MT 63–78-induced sustained activation of
AMPK alters these dynamics and does not allow cells to undergo
a correct cytockinesis, as previously shown with metformin (Vaz-
quez-Martin et al, 2009b). Recently, it has been demonstrated that
drug-induced prolonged M phase arrest leads to telomere
deprotection and activation of DNA damage response with ATM
activation and increased phosphorylation of histone H2AX
(c-H2AX), which can also be found in mitotic arrested cells
undergoing apoptosis (Rogakou et al, 2000; Hayashi et al, 2012).
Markedly increased phosphorylation of histone H2AX was indeed
observed upon mitotic block induced by MT 63–78 (Fig 5D).
Figure 5.M T 63–78 induces mitotic arrest in PCa cells.
A Cell cycle analysis in LNCaP and CRPC cells treated for 24 h with 25 lMM T6 3 –78 (MT). Percentage of cells in G1, S, and G2/M phases is indicated.
B Phase contrast and immunofluorescence (Hoechst staining) images of LNCaP and CRPC cells, following 24-h treatment with MT 63–78 (25 lM). Magnification is
indicated.
C Western blot analysis of mitotic proteins in PCa cell lysates and conditioned media, following 24-h treatment with 25 lMM T6 3 –78.
D Western blot analysis of DNA damage signaling in PCa cell lysates, following 24-h treatment with 25 lMM T6 3 –78. Treatment with 100 ng/ml Nocodazole (Noc) for
14 h was used as positive control.
Source data are available for this figure.
▸
EMBO Molecular Medicine AMPK targeting in lipogenic prostate tumors Giorgia Zadra et al
EMBO Molecular Medicine Vol 6 |N o4 | 2013 ª 2014 The Authors 524DMSO
L
N
C
a
P
 
C
L
1
 
P
C
3
 
2
2
R
v
1
 
2
2
R
v
1
 
P
h
a
s
e
 
c
o
n
t
r
a
s
t
 
H
o
e
c
h
s
t
 
0 200 400 600 800 1000
0
100
200
300
400
PE-A
54.5
30.8
13.6
02 0 0 4 0 0 6 0 0 8 0 0 1 0 0 0
0
200
400
600
PE-A
64
19.7
14.7
0 200 400 600 800 1000
0
200
400
600
PE-A
90.7
6.22
2.72
0 200 400 600 800 1000
0
200
400
600
PE-A
79.7
15.4
3.86
MT  DMSO 
MT  DMSO 
LNCaP 
22Rv1 
02 0 0 4 0 0 6 0 0 8 0 0 1 0 0 0
0
200
400
600
PE-A
68.8
21.1
7.48
DMSO 
C4-2 
0 200 400 600 800 1000
0
100
200
300
400
500
PE-A
50.3
40.1
7.97
MT 
02 0 0 4 0 0 6 0 0 8 0 0 1 0 0 0
0
100
200
300
400
500
PE-A
64.3
19.5
11.8
0 200 400 600 800 1000
0
100
200
300
PE-A
50.8
40.1
6.95
DMSO MT 
02 0 0 4 0 0 6 0 0 8 0 0 1 0 0 0
0
200
400
600
PE-A
58.5
27.4
10.9
PC3 
DMSO 
0 200 400 600 800 1000
0
100
200
300
400
PE-A
15.3
74.6
8.14
MT 
CL1 
0 200 400 600 800 1000
0
200
400
600
PE-A
68.8
20.3
7.99
C4-2B 
0 200 400 600 800 1000
0
100
200
300
400
500
PE-A
50
39.7
6.79
MT  DMSO 
C
o
u
n
t
s
 
C
o
u
n
t
s
 
C
o
u
n
t
s
 
C
o
u
n
t
s
 
C
o
u
n
t
s
 
C
o
u
n
t
s
 
A MT 63-78  B
D
p-ATM 
p-Histone H2AX 
Vinculin 
–  +  –  +  –  +  –  + 
N
o
c
 
–  +  –  + 
L
N
C
a
P
 
C
4
-
2
 
C
4
-
2
B
 
C
L
1
 
2
2
R
v
1
 
P
C
3
 
p-Histone H3 
MT 63-78 :
C Cells
100x
400x
100x
100x
100x
Conditioned media
p-ACC 
p-AMPK 
Vinculin 
p-Histone H3 
 
MT 63-78:  – + – + – + – + – + – + 
L
N
C
a
P
 
2
2
R
v
1
 
C
4
-
2
B
 
C
L
1
 
P
C
3
 
C
4
-
2
 
Cyclin B1 
L
N
C
a
P
 
2
2
R
v
1
 
PLK1  
p-Aurora 
a 
b 
c 
Cyclin B1 
Aurora B 
–  + – + –  + – + – + – + 
C
4
-
2
 
C
4
-
2
B
 
C
L
1
 
P
C
3
 
Aurora  A 
(short exposure) 
p-Histone H3 
Vinculin 
p-ACC 
Aurora  A 
(long exposure) 
MT 63-78 :
Figure 5.
Giorgia Zadra et al AMPK targeting in lipogenic prostate tumors EMBO Molecular Medicine
ª 2014 The Authors EMBO Molecular Medicine Vol 6 |N o4 | 2013 525A
MT 63-78 (μM): 0 10 25 50 
LNCaP
c-Parp
p-p53
Mcl-1
c-Caspase 3
Vinculin
0 10 25 50 
PC3 
MT 63-78 (μM): 0 10  25  50  0  10  25  50 
MT 63-78 (μM):  0 10 25 50  0 10 25 50 
0 10  25  50 
C4-2 
10 25  0 
0 10 25  50 
10 25  0 
0 10 25 50 
0 10  25 50 
C4-2B 
0 10  25 50 
CL1 
10 25 50  0 
10 25 50  0 
0 10 25 50 
22Rv1 
10 25 50  0 
10 25 50  0 
Vinculin
Vinculin
Puma
Rapamycin: 
p-ACC
-actin 
LC3-I 
LC3-II 
Short exp 
LC3-I 
LC3-II 
Long exp 
MT 63-78: 
– – +  – – +  – – + 
–  +  – –  +  – –  +  – 
+CQ  +Bafilo 
LNCaP (24 h)
Rapamycin: 
p-ACC
-actin 
LC3-I 
LC3-II 
Short exp 
LC3-I 
LC3-II 
Long exp 
MT 63-78: 
– – +  – – +  – – + 
–  +  – –  +  – – +  – 
+CQ  +Bafilo 
C
o
n
t
r
 
+
 
PC3 (48 h)
DMSO  MT 25 μM  MT 50 μM  AICAR 1 mM DMSO  MT 25 μM  MT 50 μM
L
N
C
a
P
P
C
3
P
I
Annexin V
Annexin V
P
I
C
4
-
2
C
L
1
2
2
R
v
1
B
C
17% 38% 29% 1% 25% 52%
1% 1.6% 2% 11% 14% 21% 75%
17%
12% 49%
0.4% 3% 3%
47%
11% 25%
2% 3% 3%
30%
10%
9%
16%
10%
9%
2% 6%
0.5%
Figure 6.M T 63–78 induces apoptosis in PCa cells.
A Western blot analysis of apoptosis markers, pro-apoptotic, and anti-apoptotic proteins in PCa cells lysates, after 24-h treatment with MT 63–78.
B Flow cytometry plots of Annexin V/PI assay in PCa cells, following 48-h treatment with MT 63–78. LNCaP treatment with AICAR was used as positive control.
Percentage of apoptotic cells (early and late apoptosis) is indicated in red color. Percentage of necrotic cells is depicted in blue.
C Western blot analysis of autophagic flux in LNCaP and PC3 cells, following treatement with MT 63–78 (25 lM). Lysosomal inhibitor Cloroquine (CQ, 10 lM) was
added together with MT 63–78, whereas Bafilomycin A1 (Bafilo, 400 nM) was added 6 h before harvesting. Treatment with rapamycin (10 nM) was used as positive
control. Contr+= 10 l of positive control for anti-LC3 antibody (PM036-PN).
Source data are available for this figure.
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intrinsic apoptotic pathways. We observed p53 activation, cas-
pase-3, parp cleavage, and outer membrane permeabilization in
all the models assessed, including the p53 null PC3 cells. The
extent of apoptosis in PC3 cells was however reduced with
respect to p53 wt cells (Fig 6B). To identify the underlying molec-
ular mechanisms, we evaluated the expression of the most critical
Bcl-2 family members. MT 63–78 treatment induces reduction of
anti-apoptotic Mcl-1 in concert with accumulation of the pro-
apoptotic BH3-only protein Puma (Fig 6A) in all PCa cells. In
contrast, Noxa accumulation was only observed in 22Rv1 cells.
Bcl-2 levels were moderately reduced in C4-2, C4-2B, CL1, and
22Rv1 cells. Pro-survival XIAP protein was also found reduced in
C4-2 and C4-2B cells (Supplementary Fig 8).
The induction of autophagic response upon AMPK activation has
been previously reported (Hoyer-Hansen & Jaattela, 2007; Egan
et al, 2011). However, only a modest effect of MT 63–78 on
authophagy flux was observed in LNCaP and PC3 cells following 24-
and 48-h treatment, respectively (Fig 6C).
Repression of the mTORC1 pathway does not account for the
growth inhibitory effect of AMPK direct activation
We next turned our attention on the two AMPK downstream
pathways known to play a dominant role in the control of PCa
cell growth/proliferation and survival. We, therefore, assessed the
relative contribution of mTORC1 and lipogenesis in mediating
PCa growth inhibition, following AMPK direct activation. AMPK
inhibits the mTORC1 pathway through phosphorylation of the
TSC2 complex and Raptor, whereas it affects de novo FA and
cholesterol synthesis through phosphorylation of the rate limiting
enzymes ACC and 3-hydroxy-3-methyl-glutaryl-CoA reductase
(HMGCR) and of the transcriptional regulators SREBPs, as well as
via transcriptional repression of lipogenic genes (Clarke & Hardie,
1990; Zhou et al, 2001). Both the mTORC1 (assessed by phos-
phorylation of Raptor, S6RP, and 4EBP-1) and the lipogenic path-
ways were inhibited by MT 63–78. Increased phosphorylation of
ACC was observed in LNCaP and PC3 cells while expression of
ACC and FA synthase (FASN) was also significantly downregulat-
ed (Fig 7A). Levels of the mature form of SREBP-1, responsible
for the transcription of ACC and FASN, were significantly reduced
(Fig 7B). FASN activity was repressed as well (Supplementary Fig
9A). However, when we compared MT 63–78 to the mTORC1
inhibitor rapamycin, we observed that the former caused a
greater inhibition of PCa cell growth despite a more modest
reduction of S6RP phosphorylation (Fig 7C and D). Moreover, re-
activation of the mTORC1 pathway, by transient transfection of
constitutively active and rapamycin insensitive S6 Kinase 1, was
not sufficient to rescue MT 63–78 mediated-cell growth inhibition
(LNCaP, P = 0.9950; PC3, P = 0.9740, one-way anova followed by
Tukey’s post hoc test) (Fig 7E).
Taken together, these results suggest that the blockade of the
mTORC1 pathway is not the principal mechanism responsible for
growth inhibition mediated by direct AMPK activation. In contrast
to rapamycin treatment, no increase in Akt and MAPK phosphoryla-
tion was detected in LNCaP and PC3 cells treated with MT 63–78,
suggesting that direct AMPK activation does not induce undesired
mitogenic feedback loops (Fig 7F).
Blockade of de novo lipogenesis is the key mechanism of AMPK-
mediated growth inhibition
To corroborate the inhibitory effect of MT 63–78 on lipogenesis, we
measured
14C-acetate incorporation into lipids extracted from
LNCaP cells and observed a dose-dependent reduction in
14C-ace-
tate incorporation at all the time points analyzed (Fig 8A). Compa-
rable results were observed in PC3 cells (Supplementary Fig 9B).
As expected, most of the radioactivity was incorporated into the
phospholipid fraction, with lower amounts in triacylglycerols and
other neutral lipids. AMPK activation affects primarily de novo
production of phospholipids but also significantly decreases the
production of neutral lipids (triacylglycerides, cholesterol, choles-
tererol esters, and diacylglyclerols) (Fig 8B). We then determined
whether the repression of lipogenesis accounts for MT 63–78-medi-
ated cell growth inhibition. Addition of exogenous mevalonate and
palmitate, the final products of HMGCR and FASN, rescued par-
tially but significantly LNCaP cell growth. Surprisingly, no additive
effect was observed with palmitate and mevalonate together
(Fig 8C). Of note, neither palmitate nor mevalonate showed an
effect on growth of untreated LNCaP cells (Supplementary Fig 9C).
Moreover, the addition of the ACC inhibitor TOFA and HMGCR
inhibitor simvastatin, alone or combined, inhibited cell growth sim-
ilarly to MT 63–78 (Fig 8D). These results suggest that the growth
inhibitory effect of direct AMPK activation in PCa cells is mediated
in large part through inhibition of FA and cholesterol synthesis
(Fig 8E).
MT 63–78 enhances the growth inhibitory effect of AR
signaling inhibitors
Enhanced lipogenesis is associated with the emergence of CRPC
phenotype. The current standard of care for advanced CRPC is
based on the administration of AR antagonists/inhibitors of andro-
gen synthesis. Recently, MDV3100 and abiraterone have been FDA
approved for the treatment of na€ ıve or post-docetaxel advanced
CRPC. However, emergence of treatment resistance to these new
drugs represents a major limitation. Thus, we tested whether a com-
bination treatment of MT 63–78 with AR antagonists/androgen syn-
thesis inhibitors could result in increased therapeutic response. MT
63–78 significantly enhances the growth inhibitory effect of AR
antagonists (bicalutamide and MDV3100) and abiraterone in both
LNCaP and CRPC cells (Fig 9A–C, Supplementary Fig 10). MT 63–
78 reduces AR levels and combinatorial treatments result in further
reduction of AR and PSA expression levels when compared to single
treatments (Fig 9A–C).
Direct activation of AMPK inhibits tumor growth in
xenograft models
We next sought to determine if the direct activation of AMPK could
inhibit tumor growth in an in vivo model. Thirty-two nude mice
bearing LNCaP tumors measuring 50–100 mm
3 were treated intra-
peritoneally (i.p.) with MT 63–78 at 30 mg/kg daily (n = 17) or with
5% hydroxypropyl beta-cyclodextrine as control (n = 15) for
14 days. MT 63–78 led to a 33% inhibition of tumor growth
(P = 0.049, Fig 10A). Consistent with our in vitro findings, MT 63–
78 promotes AMPK activation in xenograft tumors and inhibits the
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and Raptor phosphorylation, respectively (Fig 10B and C). Impor-
tantly, the highest levels of ACC phosphorylation were found in the
two mice showing the most significant tumor volume reduction
(Fig. 10C, black circles). Despite the fact that MT 63–78 reduced the
glycemia and improved glucose tolerance in animal models of obes-
ity and insulin resistance (Supplementary Fig 11A and B), no effect
on weight, serum glucose and triglycerides levels were observed in
non-obese nude mice maintained on normal chow diet, following
MT 63–78 treatment (Supplementary Fig 11C and D). Prolonged
treatment (21 days) with higher dose of MT 63–78 (60 mg/kg)
resulted in a more robust inhibition of LNCaP xenograft growth
(P = 0.004, end of treatment) (Fig 10D) as well as increased phar-
macodinamic markers p-ACC and p-Raptor in treated tumors com-
pared to controls (Fig 10E). Slight increase of apoptotic marker
cleaved-parp was observed in the treated tumors (Supplementary
Fig 11E). Serum PSA levels were measured at the end of the
treatment. Mean PSA level in treated group was lower than in con-
trol, although the difference did not reach statistical significance
(Fig 10F).
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Since our results demonstrated that AMPK direct activation inhibits
PCa tumor growth, we hypothesized that the loss of AMPK catalytic
alleles and, as a result, activity, would favor PCa development. Thus,
we crossed prostate specific FASN transgenic (FASN-Tg) mice,
which develop age-dependent prostate epithelial neoplasia (PIN)
(Migita et al, 2009) with AMPK a2
/ mice. At the age of 13–
16 months, 34 FASN-Tg/AMPK a2
+/+, 28 FASN-Tg/AMPK a2
+/,7
FASN-Tg/AMPK a2
/ mice were sacrificed and the three prostate
lobes (anterior, ventral, dorso-lateral) were collected for histological
examination. Despite the expression of AMPK a1 catalytic isoform
in the murine prostate, we observed increased incidence of PIN in
FASN-Tg/AMPK a2
/, suggesting that loss of a2 subunit is suffi-
cient to enhance FASN-induced tumorigenesis (Fig 10G). The odds
of PIN occurrence increase with the number of knockout alleles (logis-
tic regression P = 0.077, with post hoc calculated power of 0.44).
In vivo assessment of AMPK activation using
11C-acetate positron
emission tomography
Since acetate is a precursor for FA and cholesterol synthesis, we per-
formed Positron Emission Tomography (PET) to investigate whether
inhibition of lipogenesis by MT 63–78 was reflected by a reduction of
11C-acetate uptake by tumor xenografts. Three mice treated with MT
63–78 (30 mg/kg) or vehicle, 1 mouse treated with AICAR (400 mg/
kg), and 1 mouse treated with FASN inhibitor C75 (30 mg/kg) were
imaged with
11C-acetate PET before and after 24-h treatment with
compounds. The FASN inhibitor C75 caused a 20% reduction in the
uptake, whereas AICAR induced a slight increase (16%). No differ-
ence was observed with MT 63–78 (Fig 11A). These results are con-
sistent with the role of activated AMPK in promoting nutrients
uptake, their catabolism for ATP production, and mitochondrial bio-
genesis (Steinberg & Kemp, 2009). To investigate whether reduction
in
11C-acetate uptake for lipids synthesis may be compensated for by
increased uptake for its oxidation, we incubated LNCaP cells, previ-
ously treated with MT 63–78 and AICAR for 4 h, with
14C-acetate
(2uCi) for 2 h. At the end of the treatment, the production of
14C-CO2
was measured. A significant increase in
14C-CO2 was observed, con-
firming that AMPK activation promotes acetate oxidation in the TCA
(Fig 11B). No increase in
14C-CO2 production was observed after
30 min of AMPK activation, consistent with our previous data show-
ing no difference in ATP levels at that time point (Fig 2C).
Discussion
The master metabolic regulator AMPK has recently emerged as a
potential therapeutic target for cancer treatment. AMPK activators
such as AICAR and metformin have been shown to inhibit PCa
growth in culture, in xenografts, and in genetically engineered
mouse models (GEMMs) (Xiang et al, 2004; Huang et al, 2008;
Zakikhani et al, 2008). Moreover, epidemiologic data including big-
uanides, physical activity, caloric restriction, and increased adipo-
nectin levels have been reported to both activate AMPK and lower
cancer risk, including PCa (Jiang et al, 2008; McTiernan, 2008; Li
et al, 2010). However, AMPK-independent effects of drugs tested to
date (Ben Sahra et al, 2008, 2011; Moreno et al, 2008; Garcia-Garcia
et al, 2009; Kalender et al, 2010; Santidrian et al, 2010) prevented
investigators to unequivocally determine whether AMPK activation
was the necessary and sufficient mechanism of inhibiting carcino-
genesis. In search for an adequate tool to address this unresolved
question, we characterized and utilized in our experiments the
novel AMPK direct activator MT 63–78. This new tool allowed us
demonstrating that AMPK activation itself is necessary and suffi-
cient for the suppression of PCa cell growth, in both androgen-
dependent and CRPC models. Importantly, the growth inhibitory
response to MT 63–78 was not affected by the status of the upstream
AMPK-activating kinase LKB1. Since 30% of somatic NSCLCs har-
bor LKB1 inactivating mutations, often associated with KRAS muta-
tions (Mahoney et al, 2009; Shackelford & Shaw, 2009), our results
open new therapeutic opportunities for LKB1 deficient and LKB1
deficient/KRAS activated tumors.
The use of a complementary approach with a mouse model of
genetic ablation of a2 subunit in the context of FASN overexpression
underscored the crucial role of AMPK pathway in PCa progression,
Figure 7. Inhibition of mTORC1 is only partially responsible for the anti-growth effects of MT 63–78.
A Western blot analysis of lipogenic and mTORC1 pathways, after incubation with MT 63–78 for the indicated time points. ACC = Acetyl-CoA carboxylase,
FASN = fatty acid synthase, S6RP = S6 ribosomal protein, 4EBP-1 = 4 element binding protein 1. AICAR (1 mM) was used as positive control.
B Expression levels of precursor and mature forms of SREBP-1, following MT 63–78 (25 lM) treatment for the indicated time points.
C Relative growth of LNCaP and PC3 cells after 3-day treatment with MT 63–78 (MT) or rapamycin (Rapa). Results are expressed as mean  s.d. of three independent
samples. One-way ANOVA test, followed by Tukeys post hoc test for multiple comparisons was performed and adjusted P values were calculated (LNCaP:
***P = 5.11E-08 MT versus DMSO; ***P = 1.45E-06 Rapa 1 nM versus DMSO; ***P = 2.47E-06 Rapa 100 nM versus DMSO;
###P = 0.000152 MT versus Rapa 1 nM;
###P = 0.000393 MT versus Rapa 100 nM. PC3: ***P = 1.63E-07 MT versus DMSO; ***P = 6.09E-06 Rapa 1 nM versus DMSO; ***P = 1.53E-06 Rapa 100 nM versus
DMSO;
###P = 0.000438 MT versus Rapa 1 nM;
##P = 0.00763 MT versus Rapa 100 nM).
D Expression levels of phosphorylated ACC, Raptor, AMPK, S6RP, and their total forms after 3-day treatment with MT 63–78 (25 lM) and rapamycin (Rapa).
E Relative growth of LNCaP and PC3 cells transfected with empy vector (pKH3-EV) or with a construct containing constitutively active, rapamycin insensitive, S6
kinase 1 (pKH3-HA-S6K1 CA). Count was performed 3 days after incubation with MT 63–78 (25 lM) or rapamycin (1 nM). Drugs were added 12 h post-transfection.
Results are expressed as a percentage of control (DMSO-treated cells)  s.d. of three independent samples. One-way ANOVA test, followed by Tukeys post hoc test
for multiple comparisons was performed and adjusted P values were calculated (LNCaP-pKH3-EV: ***P < 0.0001 MT versus DMSO; **P = 0.0089 Rapa versus DMSO.
LNCaP-pKH3-HA-S6K1 CA: ***P = 0.0008 MT versus DMSO. PC3-pKH3-EV: ***P = 0.0003 MT versus DMSO; **P = 0.0088 Rapa versus DMSO. PC3-pKH3-HA-S6K1 CA:
***P = 0.0005 MT versus DMSO). n.s. = non significant.
F Feedback activation of Akt and p42/p44 MAPK after 72-h incubation with MT 63–78 (25 lM) or rapamycin (Rapa).
Source data are available for this figure.
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Figure 8. The anti-growth effects of MT 63–78 are mediated by inhibition of lipogenesis.
A Incorporation of
14C-acetate into lipids, following treatment with MT 63–78 (MT). Results are expressed as a percentage of
14C-acetate incorporation into lipids
compared to control, normalized to protein content. Mean values  s.d. of three independent experiments are shown. One-way ANOVA test, followed by Dunnett’s
post hoc test for multiple comparisons was performed and adjusted P values were calculated (LNCaP-12 h: **P = 0.0018 MT 25 lM versus DMSO; ***P = 0.0004
MT 50 lM versus DMSO. LNCaP-24 h: *P = 0.0230 MT 25 lM versus DMSO; **P = 0.0014 MT 50 lM versus DMSO; LNCaP-48 h: ***P = 0.0003 MT 25 lM versus
DMSO; ***P = 5.04E-05 MT 50 lM versus DMSO).
B
14C-acetate incorporation in different lipid species. Data are expressed in cpm normalized to protein content. PL = Phospholipids, TG = Triacylglycerols,
CE = Cholesterol esters, Chol = Cholesterol, DAG = Diacylglycerols.
C Relative cell growth after 3-day treatment with MT 63–78 (MT) alone or in combination with 75 lM palmitate (Pal) and/or 100 lM mevalonate (Mev). Results are
expressed as mean  s.d. of five independent samples. One-way ANOVA test, followed by Tukeys post hoc test for multiple comparisons was performed and
adjusted P values were calculated (***P = 2.4E-09 MT versus DMSO;
###P = 0.000573 MT+Pal versus MT;
###P = 6.96E-05 MT+Mev versus MT;
###P = 4.97E-05
MT+Pal+Mev versus MT).
D Relative cell growth after 3-day treatment with MT 63–78 (25 lM), tofa (10 lg/ml), simvastatin (Simv, 10 lM), and their combination. Results are expressed as
mean  s.d. of three independent samples. One-way ANOVA test, followed by Tukeys post hoc test for multiple comparisons was performed and adjusted P values
were calculated (***P = 1.13E-08 MT versus DMSO; ***P = 2.26E-08 Tofa versus DMSO; ***P = 3.17E-08 Simv versus DMSO; ***P = 4.82E-09 Tofa+Simv versus
DMSO).
E Working model for MT 63–78. LKB1 = liver kinase B1, CaMKKb = calcium/calmodulin-dependent protein kinase kinase-b, ACC = Acetyl-CoA carboxylase, HMG-
CoA = 3-Hydroxy-3-methyl-glutaryl-CoA, PI3K = phosphatidylinositol 3-kinase, TSC1/TSC2 = tuberous sclerosis complex 1/2, Rheb = Ras homolog enriched in brain,
mTORC1 = mammalian target of rapamycin complex 1, 4EBP-1 = 4E-binding protein 1, S6K = S6 kinase, eiF4E = Eukaryotic translation initiation factor 4E,
PL = Phospholipids, TG = Triacylglycerols. Color code: blue = activation; red = inhibition.
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Faubert et al, 2013) and further supports the potential of targeting
AMPK axis for PCa treatment.
Cell cycle analysis shows that MT 63–78 induces mitotic arrest
with accumulation/activation of cyclin B1, Aurora kinases A and
B, and PLK1, involved in mitotic spindle assembly, chromosome
segregation and cytokinesis. These results are in line with litera-
ture observations highlighting the role of AMPK as cell cycle
regulator, beyond its metabolic activity (Lee et al, 2007; Vazquez-
Martin et al, 2009a,b,c; Banko et al, 2011). From these studies it
has emerged that a fine-tuned biphasic activation of AMPK is
required for proper mitotic progression, whereas any alteration of
AMPK expression or function (obtained by pharmacological sus-
tained activation or AMPK depletion) alters its spatial and tempo-
ral regulation, resulting in microtubule misalignement, spindle
misorientation, abnormal chromosome segregation followed by
mitotic catastrophe and polyploidy (Vazquez-Martin et al, 2009b;
Banko et al, 2011; Thaiparambil et al, 2012). Our data are also
supported by recent experiments done in our laboratory, using
synchronized HeLa cells as model, which show that increased de
novo fatty acid synthesis concomitant to reduced AMPK activity
and phosphorylation of ACC is required for cytokinesis initiation
(Natalia Scaglia, unpublished results). In this view, AMPK orches-
trates the completion of mitosis by coordinately regulating mitotic
spindle assembly, chromosomal segregation, and cytoskeleton
rearrangement with membrane synthesis. Thus, MT 63–78 induced
mitotic arrest could be ascribed to both a persitent AMPK-medi-
ated inhibition of de novo FA synthesis (metabolic role) as well
as to mitotic spindle assembly/chromosome segregation abnormal-
ities (non-metabolic role). Moreover, we observed induction of
DNA damage signaling following prolonged mitotic arrest, which
potentially serves as a mitotic duration checkpoint, responsible for
eliminating cells that fail to progress through mitosis properly.
Indeed, activation of the intrinsic apoptotic pathway was observed
in our PCa models concurrent to Puma accumulation and reduc-
tion of Mcl-1 expression. This is consistent with the finding that
AMPK activation by AICAR or upon block of glycolysis results in
mTORC1 inhibition-dependent decrease of Mcl-1 through regula-
tion of its translation (Pradelli et al, 2010). Interestingly, we also
observed cell cycle arrest and apoptosis in p53-deficient context,
suggesting that MT 63–78 might also be suitable for the treatment
of p53 null/mutated PCas not responsive to biguanides (Ben Sahra
et al, 2011).
PCa is characterized by alterations in the PI3k/Akt/mTOR path-
way and by a unique lipogenic reprogramming, active both at
tumor initiation and in advanced stages (Suburu & Chen, 2012).
Since multiple components of the PI3k/Akt/mTOR pathway are
deregulated in a wide variety of solid tumors, considerable atten-
tion has been focused on the biochemical and genetic characteriza-
tion of this pathway in cancer and on developing new drugs to
inhibit it (Wong et al, 2010; Laplante & Sabatini, 2012). However,
activation of de novo lipogenesis has recently been recognized, not
only as an adaptation to fulfill the metabolic requirements of
highly proliferating cancer cells, but as a hallmark of tumorigene-
sis, tumor progression, chemoresistance, and development of
androgen-resistance (Ettinger et al, 2004; Santos & Schulze, 2012).
Newly synthesized lipids affect a number of cellular processes
such as membrane biogenesis, signal transduction, intracellular
trafficking, and lipid-based protein modification to promote pros-
tate cancer cell proliferation and survival (Zadra et al, 2013).
Indeed, overexpression and increased activity of FASN, a key
enzyme responsible for the terminal step in FA synthesis, repre-
sents one of the most frequent phenotypic alterations in cancer
cells (Brusselmans & Swinnen, 2009; reviewed in Flavin et al,
2011). Our data support the essential role of lipogenesis in PCa
maintenance and progression and point out that AMPK-mediated
repression of lipogenesis plays a dominant role in tumor growth
inhibition.
Androgens are the major drivers of PCa carcinogenesis and pro-
gression and AR signaling is still active in castration resistant dis-
ease. Thus, targeting AR pathway remains the gold standard for
both androgen sensitive and CRPCs. The AR antagonist MDV3100
and the CYP17A1 inibitor abiraterone have been FDA approved for
the treatment of CRPC. However, despite encouraging results,
emergence of treatment resistance represents a major limitation
(Yuan et al, 2013). Previous studies have underscored the tight
connection between AR signaling and increased de novo lipogene-
sis, expecially in the context of emergence of androgen indepen-
dence (Swinnen et al, 1997; Ettinger et al, 2004), suggesting that
targeting lipogenesis will be particularly beneficial in CRPC. Our
data showing MT 63–78-mediated growth inhibitory effect in CRPC
models and the discovery of lipogenesis inhibition as the effector
arm of AMPK-mediated suppression of PCa growth, prompted us
to evaluate whether combination of AR signaling inhibitors and
direct AMPK activation would result in a potentiated growth ini-
hibitory effect. Low concentration of MT 63–78 was sufficient to
significantly enhance the rate of growth inhibition induced by AR
antagonists bicalutamide, MDV3100 or by the steroidogenesis
inhibitor abiraterone (recently also discovered as AR antagonist)
(Richards et al, 2012). This enhanced anti growth effect also corre-
lates with reduction in AR expression and activity (PSA produc-
tion). These results support previous data using combination of
bicalutamide and the indirect activator metformin (Colquhoun
et al, 2012) and point to the crucial role of AMPK activation rather
than the inhibition of the insulin pathway in mediating the addi-
tive effect of the combinatorial treatment. Results from the phase
II clinical trial NCT01677897, which evaluates the impact of the
addition of metformin to abiraterone in metastatic PCa patients,
will also inform on the benefit of adjuct AMPK activators to cur-
rent standard treatments.
PET is the most advanced technique for metabolic imaging and
one of the most accurate tools for tumor staging in the pre-treatment
and follow-up phases. Vavere et al showed a reduced tumor uptake
of
11C-acetate in mice treated with FASN inhibitor C75, providing
validation for development of
11C-acetate PET as measure of FA syn-
thesis (Vavere et al, 2008). Thus, we investigated whether
11C-ace-
tate could serve as in vivo biomarker of response to AMPK
activation therapy. While our data with C75 fully confirm their find-
ings, we report no decrease in
11C-acetate uptake following MT 63–
78 treatment, showing that this is compatible with AMPK-mediated
induction of
11C-acetate uptake for oxidation in the TCA cycle, con-
current with inhibition of FA synthesis. Our results thus discourage
the use of
11C-acetate to monitor treatment with AMPK activators
in the clinical setting, while the proliferation marker fluoro-L-
thymidine (
18F-FLT) might be a promising alternative (Habibollahi
et al, 2013).
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underpinning for direct targeting of AMPK in PCa therapy, with the
downregulation of lipogenesis representing the major downstream
effect of this therapeutic approach. This study set also the ground-
work for testing the combination of AMPK activators and AR signal-
ing inhibitors in CRPC pre-clinical models.
Materials and Methods
Chemicals
A detailed list of the reagents used in the study is provided in the
Supplementary materials and methods.
Cell lines and culture conditions
Cell lines were maintained and cultured as described in the Supple-
mentary materials and methods.
Western blot analysis
Western blotting was performed as described in the Supplementary
materials and methods.
Pharmacokinetic experiments
MT 63–78 was administered i.p. or orally using the antiacid Mylanta
as vehicle in three C57 BL/6 male mice. Compound concentration in
the plasma was measured by HPLC/MS, as described in the Supple-
mentary materials and methods.
Measurement of AMPK activity
AMPK activity in total cell lysates was measured using CycLex
AMPK Kinase Assay kit (MBL International Corporation) or alpha
screen technology (Perkin Elmer), according to the manufacturer’s
instructions. In vitro AMPK activity was assessed using recombinant
human AMPK (a1b1c1, a2b1c1, a1b2c1, a2b2c1) and alpha screen
technology. Details are provided in the Supplementary materials
and methods.
Kinome screen
Kinase profiling was performed using The Upstate
  KinaseProfiler
service from Millipore.
AMPK dephosphorylation assay
AMPK dephosphorylation experiments using recombinant AMPK
a1b1c1 were performed as described in the Supplementary materials
and methods.
Measurement of ATP, ADP, AMP levels
Measurment of intracellular ATP, ADP, AMP levels were carried out
using commercial kits and HPLC, as described in the Supplementary
materials and methods.
Transient transfection experiments
Details regarding siRNA and plasmids are provided in the Supple-
mentary materials and methods.
Cell growth, viability, and soft agar assays
Cell growth was assessed by counting number of viable cells using
the Vi-cell automatic counter (Beckman). Viability (% of viable
cells/total cells) was also measured using the trypan blue exclusion
method. Soft agar assays were performed as described in the Supple-
mentary materials and methods.
Cell cycle and apoptosis studies
Cell cycle and apoptosis studies were performed by flow citometry
and western blotting as described in the Supplementary materials
and methods.
Hoechst staining
Staining with Hoechst 33342 was performed according to standard
procedures. Details are provided in the Supplementary materials
and methods.
Figure 9.M T 63–78 enhances the growth inhibitory effect of ADT.
A Relative growth of LNCaP and CRPC cells C4-2 and 22Rv1, following 3-day treatment with MT 63–78 (MT), AR antagonist bicalutamide (Bic), and combined
treatment (MT+Bic). Results are expressed as mean  s.d. of three independent samples. One-way ANOVA test, followed by Tukeys post hoc test for multiple
comparisons was performed and adjusted P values were calculated (**P < 0.01, ***P < 0.001 MT versus MT+Bic;
##P < 0.01,
###P < 0.001 Bic versus MT+Bic).
Exact P values for each comparison are reported in Supplementary materials and methods. Expression levels of AR and PSA following single or combined treatments
are shown under the bar graphs.
B Relative growth of LNCaP and CRPC cells C4-2 and 22Rv1, following 3-day treatment with MT 63–78 (MT), AR antagonist MDV3100 (MDV), and combined treatment
(MT+MDV). Results are expressed as mean  s.d. of three independent samples. One-way ANOVA test, followed by Tukeys post hoc test for multiple comparisons
was performed and adjusted P values were calculated (***P < 0.001 MT versus MT+MDV;
###P < 0.001 MDV versus MT+MDV). Exact P values for each comparison
are reported in Supplementary materials and methods. Expression levels of AR and PSA following single or combined treatments are shown under the bar graphs.
C Relative growth of LNCaP and CRPC cells C4-2 and 22Rv1, following 3-day treatment with MT 63–78 (MT), CYP17A1 inhibitor abiraterone (Abi) and combined
treatment (MT+Abi). Results are expressed as mean  s.d. of three independent samples. One-way ANOVA test, followed by Tukeys post hoc test for multiple
comparisons was performed and adjusted P values were calculated (**P < 0.01, ***P < 0.001 MT versus MT+Abi;
###P < 0.001 Abi versus MT+Abi). Exact P values
for each comparison are reported in Supplementary materials and methods. Expression levels of AR and PSA following single or combined treatments are shown
under the bar graphs.
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Figure 10. In vivo effects of AMPK activation.
A Average tumor volume of LNCaP xenografts during 14-day treatment with MT 63–78 (30 mg/kg, i.p.). Experiments were performed twice for a total number of 17
mice under treatment and 15 controls. Results are expressed as n fold the mean initial volume (equal to 1)  s.e.m. (*P = 0.049, end of treatment, Unpaired t-test).
B Representative image of treated and control mice (with similar pre-treatment tumor volume) and their excised tumors at sacrifice. Correspondent western blot
analysis of key proteins belonging to lipogenic and mTORC1 pathways is shown.
C Densitometric analysis of phosphorylated ACC and Raptor in tumor homogenates of all treated mice (n = 16) and controls (n = 15). One treated mouse was not
included in the analysis because frozen material was not available. Highlighted (black circle) are the two tumors with the highest ACC phosphorylation and volume
reduction. Results are expressed in arbitrary units, after normalization to Vinculin. Unpaired t-test and Wilcoxon Mann–Whitney t-test were performed. Significant
P values are reported on the graphs.
D Average tumor volume of LNCaP xenografts during 21-day treatment with MT 63–78 (60 mg/kg, i.p., five mice) and vehicle (six mice). Results are expressed as n fold
the mean initial volume (equal to 1)  s.e.m. (**P = 0.004, end of treatment, Wilcoxon Mann–Whitney test). One mouse from treated group was removed from the
study since biochemical analysis showed that the drug for unknown reasons did not penentrate in the tumor.
E Densitometric analysis of phosphorylated ACC and Raptor performed as in C. Unpaired t-tests were performed. Significant P values are reported on the graphs.
F Serum PSA levels measured at the end of the 21-day treatment with MT 63–78 (60 mg/kg, i.p.) in five treated and five control mice. Results are expressed as mean
 s.e.m. ELISA was performed twice (each sample in duplicate) with similar results. A representative experiment is shown. Serum from one control mouse was not
available. Unpaired t-test was performed (P = 0.27).
G PIN incidence in FASN-Tg a2
+/+ (n = 34), FASN-Tg/AMPK a2
+/ (n = 28), FASN-Tg/AMPK a2
/ (n = 7) age-matched mice. Logistic regression P = 0.077, with post hoc
calculated power of 0.44.
Source data are available for this figure.
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FASN activity in PCa cell lines was measured as previously
described (Kuhajda et al, 1994). Details are provided in the Supple-
mentary materials and methods.
2-
14C-acetate incorporation into lipids and thin
layer chromatography
2-
14C-acetate incorporation into lipids and Thin Layer Chromatogra-
phy (TLC) were performed as previously described (Bligh & Dyer,
1959; Bagnato & Igal, 2003) Details are provided in the Supplemen-
tary materials and methods.
2-
14C -acetate oxidation experiments
2-
14C -acetate oxidation experiments were performed using a stan-
dard protocol as described in the Supplementary materials and
methods.
Xenograft, GEMMs, and PET imaging
All animal studies were carried out in compliance with National and
DFCI guidelines. A detailed description of animal studies (drug treat-
ments, GEMMs, and PET imaging) is provided in the Supplementary
materials and methods.
Histopathology
Collection of murine prostate and histological procedures were
performed as described in the Supplementary materials and meth-
ods. Hematoxylin and eosin staining was blindly evaluated by an
expert pathologist (Sabina Signoretti) for the presence of prostate
lesions.
Measurement of serum PSA, glucose, and triglycerides
Serum PSA levels were measured using Total Prostate-Specific Anti-
gen ELISA kit (Alpco). Glucose levels were measured glucometer
(Abbott) and QuantiChrom
TM Glucose Assay Kit (Bio Assays Sys-
tems). Triglycerides were measured by serum triglyceride Determi-
nation Kit (Sigma), as described by the manufacturer.
Statistical analysis
Statistical analyses were done using two-tailed, unpaired t-test,
Wilcoxon Mann-Whitney test, one-way analysis of variance (ANO-
VA) followed by post-hoc Bonferroni, Tukey’s or Dunnett’s tests,
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Figure 11.
11C-acetate PET in LNCaP xenograft treated with AMPK activators.
A
11C-acetate micro-PET imaging before and after i.p. treatment with vehicle (5% hydroxypropyl beta-cyclodextrine) or AMPK activators MT 63–78 and AICAR. FASN
inhibitor C75 was used as positive control. Fire LUT images of tumor-bearing mice, after 15 min of i.v. injection of
11C-acetate, are shown. Arrows mark tumor
location. Maximal and mean standardized uptake volumes (SUVs) are indicated.
B
14C-acetate oxidation in LNCaP cells, following 6-h treatment with MT 63–78 (MT) or AICAR.
14C-CO2 was measured in cpm and normalized to protein content, after
background subtraction. Results are expressed as mean  s.d. of three independent samples. One-way ANOVA test, followed by Dunnett’s post hoc test for multiple
comparisons was performed and adjusted P values were calculated (*P = 0.0109 MT 25 lM versus DMSO; **P = 0.0051 MT 50 lM versus DMSO; **P = 0.0016
AICAR versus DMSO).
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using the Graphpad software, version 5d, StatPlus: mac 2009, and
R statistic packages. P values < 0.05 were considered significant.
Logistic regression analysis was performed using R statistics
packages.
Supplementary information for this article is available online:
http://embomolmed.embopress.org
Acknowledgements
We thank Dr. Benoit Viollet for providing AMPK a1
//a2
/ MEFs and
AMPK a2
/ mice, Dr. Nabeel El-Bardeesy for LKB1
/ MEFs, all the
researchers at DFCI, BIDMC, and MGH that provided us the cancer cell
lines described in the manuscript, and Dr. John Blenis for the constitutive
active S6K1 plasmid. We thank Joshua Rose, Debora C Bastos, John Cloh-
essy, Bhavik Padmani, and Sudeepa Syamala for their support with the in
vivo studies. We thank Michael Peterson for his support with immunoflu-
orescence experiments, Jane Hayward for graphical support, and Stefano
Cacciatore for statistical support. Finally, we are grateful to Drs. Arkaitz
Carracedo and Nabeel El-Bardeesy for their critical reading of the manu-
script and to Dr. Emanuele Palescandolo for the helpful discussions. This
work was supported by the Prostate Cancer Foundation, the DF/HCC
SPORE in Prostate Cancer (NIH/NCI P50 CA90381), and NIH grant
RO1CA131945 to ML. GZ was supported by fellowships from University of
Milan, American Italian Cancer Foundation, and Andrea e Libi Lorini Foun-
dation.
The paper explained
Problem
While metabolic reprogramming is now recognized as a hallmark of
tumorigenesis and tumor progression, the development of metabolic-
targeted therapy remains a challenge. Epidemiologic and experimental
studies have identified the energy sensor AMPK as an ideal target not
only for metabolic diseases but also for cancer. While biguanides such
as metformin have cancer preventing/therapeutic properties, their
metabolic effects beyond AMPK activation leave unanswered the
question of whether AMPK activation per se is necessary and sufficient
to affect tumor growth.
Results
Utilizing a novel, highly specific AMPK direct activator, we show that
AMPK activation per se inhibits PCa cell growth in vitro and in vivo,
whereas the allelic loss of AMPK catalytic subunits fosters PCa devel-
opment. In addition, we report that AMPK anti-tumor effects are inde-
pendent of the status of its upstream activator, the tumor suppressor
LKB1. From a mechanistic standpoint, we demonstrate that inhibition
of de novo lipogenesis is the dominant downstream effector of AMPK-
mediated inhibition over mTORC1. Finally, we demonstrate that
co-treatment of the direct AMPK activator with AR signaling inhibitors
results in significantly enhanced growth inhibition in both androgen
sensitive and CRPC models.
Impact
This study proposes AMPK as a crucial metabolic hub that can be tar-
geted in PCa. Because suppression of lipogenesis is the predominant
effector arm of AMPK activation, AMPK activators may be especially
effective in lipogenesis-driven tumors. Combining AMPK activators
with hormonal therapy results in a synergistic anti-cancer effect. PET
imaging can be utilized as a non-invasive biomarker of efficacy of
metabolic therapy.
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